Subtype-specific activity of drugs in relapsed/refractory nodal PTCLs
| Drug . | Target . | n . | ORR, CR rate . | PTCL, NOS . | ALCL . | AITL/TFH . |
|---|---|---|---|---|---|---|
| FDA approved or NCCN compendium listed | ||||||
| Belinostat10 | HDAC | 120 | ORR 25.8% CR 10.8% | n = 77 ORR 23.3% | n = 15 ORR 13.3% | n = 22 ORR 45.5% |
| Romidepsin11 | HDAC | 130 | ORR 25% CR 15% | n = 69 ORR 29% CR 14% | n = 21 ORR 24% CR 19% | n = 27 ORR 30% CR 19% |
| Pralatrexate12 | Folate | 109 | ORR 29% CR 11% | n = 59 ORR 32% | n = 17 ORR 35% | n = 13 ORR 8% |
| Brentuximab vedotin13,14 | CD30 | n/a | n/a | n = 22 ORR 33% CR 14% | n = 50 ORR 86% CR 57% | n = 13 ORR 54% CR 38% |
| Duvelisib15 | PI3K-δ,γ | 101 | ORR 49% CR 34% | n = 52 ORR 48.1% CR26.9% | n = 15 ORR 13.3% CR 13.3% | n = 30 ORR 66.7% CR 53.3% |
| Ruxolitinib16 | JAK1/2 | 53 | ORR 25% CR 6% | n = 12 ORR 18% CR 9% | n = 4 ORR 25% CR 25% | n = 9 ORR 33% CR 11% |
| Lenalidomide17 | Various | 39 | ORR 26% CR 8% | n = 14 ORR 43% CR 14% | n = 10 ORR 10% CR 0 | n = 9 ORR 33% CR 11% |
| Bendamustine18 | Various | 60 | ORR 50% CR 28% | n = 23 NR | n = 2 NR | n = 32 NR |
| Gemcitabine19 | Various | 20 | ORR 55% CR 30% | NR | NR | NR |
| Crizotinib20 | ALK | n/a | n/a | n/a | ALK-pos n = 26 ORR 83%-90% CR 80%-83% | n/a |
| Alectiinib21 | ALK | n/a | n/a | n/a | ALK-pos n = 10 ORR 80% CR 60% | n/a |
| Investigational agents | ||||||
| Valemestatat22 | EZH1/2 | 119 | ORR 43.7% CR 14.3% | n = 41 ORR 31.7% CR 9.8% | n = 9 ORR 33.3% CR 11.1% | n = 50 ORR 54% CR 18% |
| Golidocitinib23 | JAK1 | 80 | ORR 43.8% CR 25% | ORR 45.7% | ORR 11.1% | ORR 56.3% |
| Chidamide24 | HDAC | 79 | ORR 28% CR 14% | n = 27 ORR 22% CR 7% | n = 17 ORR 41% CR 24% | n = 10 ORR 50% CR 40% |
| Selected novel combinations | ||||||
| Romidepsin plus azacytidine25 | Epigenetic modification | 13 | ORR 54% CR 38% | NR | NR | n = 15∗ ORR 80% CR 60% |
| Romidepsin plus duvelisib26 | HDAC and PI3K-δ,γ | 53 | ORR 58% CR 42% | n = 19 ORR 53% CR 32% | n = 3 ORR 100% CR 67% | n = 19 ORR 68% CR 58% |
| Romidepsin plus lenalidomide27 | HDAC and immune modulatory | 15 | ORR 53%, CR 13% | n = 5 ORR 40% CR 0 | NR | n = 2 ORR 100% CR 50% |
| Drug . | Target . | n . | ORR, CR rate . | PTCL, NOS . | ALCL . | AITL/TFH . |
|---|---|---|---|---|---|---|
| FDA approved or NCCN compendium listed | ||||||
| Belinostat10 | HDAC | 120 | ORR 25.8% CR 10.8% | n = 77 ORR 23.3% | n = 15 ORR 13.3% | n = 22 ORR 45.5% |
| Romidepsin11 | HDAC | 130 | ORR 25% CR 15% | n = 69 ORR 29% CR 14% | n = 21 ORR 24% CR 19% | n = 27 ORR 30% CR 19% |
| Pralatrexate12 | Folate | 109 | ORR 29% CR 11% | n = 59 ORR 32% | n = 17 ORR 35% | n = 13 ORR 8% |
| Brentuximab vedotin13,14 | CD30 | n/a | n/a | n = 22 ORR 33% CR 14% | n = 50 ORR 86% CR 57% | n = 13 ORR 54% CR 38% |
| Duvelisib15 | PI3K-δ,γ | 101 | ORR 49% CR 34% | n = 52 ORR 48.1% CR26.9% | n = 15 ORR 13.3% CR 13.3% | n = 30 ORR 66.7% CR 53.3% |
| Ruxolitinib16 | JAK1/2 | 53 | ORR 25% CR 6% | n = 12 ORR 18% CR 9% | n = 4 ORR 25% CR 25% | n = 9 ORR 33% CR 11% |
| Lenalidomide17 | Various | 39 | ORR 26% CR 8% | n = 14 ORR 43% CR 14% | n = 10 ORR 10% CR 0 | n = 9 ORR 33% CR 11% |
| Bendamustine18 | Various | 60 | ORR 50% CR 28% | n = 23 NR | n = 2 NR | n = 32 NR |
| Gemcitabine19 | Various | 20 | ORR 55% CR 30% | NR | NR | NR |
| Crizotinib20 | ALK | n/a | n/a | n/a | ALK-pos n = 26 ORR 83%-90% CR 80%-83% | n/a |
| Alectiinib21 | ALK | n/a | n/a | n/a | ALK-pos n = 10 ORR 80% CR 60% | n/a |
| Investigational agents | ||||||
| Valemestatat22 | EZH1/2 | 119 | ORR 43.7% CR 14.3% | n = 41 ORR 31.7% CR 9.8% | n = 9 ORR 33.3% CR 11.1% | n = 50 ORR 54% CR 18% |
| Golidocitinib23 | JAK1 | 80 | ORR 43.8% CR 25% | ORR 45.7% | ORR 11.1% | ORR 56.3% |
| Chidamide24 | HDAC | 79 | ORR 28% CR 14% | n = 27 ORR 22% CR 7% | n = 17 ORR 41% CR 24% | n = 10 ORR 50% CR 40% |
| Selected novel combinations | ||||||
| Romidepsin plus azacytidine25 | Epigenetic modification | 13 | ORR 54% CR 38% | NR | NR | n = 15∗ ORR 80% CR 60% |
| Romidepsin plus duvelisib26 | HDAC and PI3K-δ,γ | 53 | ORR 58% CR 42% | n = 19 ORR 53% CR 32% | n = 3 ORR 100% CR 67% | n = 19 ORR 68% CR 58% |
| Romidepsin plus lenalidomide27 | HDAC and immune modulatory | 15 | ORR 53%, CR 13% | n = 5 ORR 40% CR 0 | NR | n = 2 ORR 100% CR 50% |
FDA, US Food and Drug Administration; n/a, not applicable; NCCN, National Comprehensive Cancer Network; NR, not reported.
Includes treatment-naïve and relapsed/refractory patients.